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Strengths and limitations of this study
 ► To the best of our knowledge, this study will be the 
first systematic review that will comprehensively 
compare and explore the impact of pneumococcal 
conjugate vaccine (PCV) on carriage, pneumococcal 
pneumonia (invasive and non- invasive) and mor-
tality associated with the disease prevaccine and 
postvaccine introduction in adults and other at risk 
groups living in Africa.
 ► Small number of studies eligible across regions 
could impact the quality of our estimates.
 ► Presence of high heterogeneity across studies, par-
ticularly in countries where PCV7, PCV10 or PCV13 
were in use around the same time and were sero-
typing was only done for vaccine- type pneumococ-
cal strains.
AbStrACt
Introduction Africa harbours a high burden of 
pneumococcal disease, with associated high mortality 
rates. Despite 34 countries introducing the pneumococcal 
conjugate vaccine, which reduces the risk of 
pneumococcal carriage (a prerequisite for disease) of 
some of the most pathogenic pneumococcal serotypes, 
it remains uncertain whether they will achieve the 
sustained direct or indirect protection necessary to reduce 
pneumococcal carriage to levels sufficient to interrupt 
transmission and disease. We will therefore summarise 
the available data on the impact of the pneumococcal 
conjugate vaccine in reducing vaccine serotype carriage 
and pneumococcal pneumonia in Africa between 2000 and 
2019.
Methods and analysis Using a predetermined search 
strategy, we will conduct a comprehensive search of 
PubMed, MEDLINE database, the Excerpta Medica 
Database, the ISI Web of Science (Science Citation Index), 
Scopus and the African Index Medicus to identify published 
studies reporting the prevalence of Streptococcus 
pneumoniae carriage (vaccine type and non- vaccine 
type), incidence rates of pneumococcal pneumonia and 
mortality among children, adults and HIV- infected (all- 
ages) pre- pneumococcal conjugate vaccine (PCV) and 
post- PCV introduction (published between 1st January 
2000 and 31st December 2019) in African countries 
that have introduced PCVs (PCV7/PCV10/PCV13) in their 
routine national immunisation programme. The studies 
retained and data extracted will be assessed for bias using 
prevalidated tools and checklists. Heterogeneity across 
studies will be assessed using the χ2 test on Cochrane Q 
statistic. A random effect meta- analysis will be used to 
estimate the overall prevalence of pneumococcal carriage 
and incidence of pneumococcal pneumonia across studies 
with similar characteristics. Results will be reported in 
compliance with the Meta- Analysis Of Observational 
Studies in Epidemiology guidelines. The protocol has 
been prepared in accordance to the 2015 guidelines on 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses.
Ethics and dissemination This systematic review will 
not require ethical approval as we will be using already 
published data. The final manuscript will be submitted for 
publication in a peer- reviewed journal and presented at 
conferences.
PrOSPErO registration number CRD42019130976.
IntrOduCtIOn
Streptococcus pneumoniae (‘the pneumo-
coccus’) is a common coloniser of the naso-
pharynx and a major cause of morbidity and 
mortality among children under the age of 
5 years worldwide.1 2 High rates of pneumo-
coccal disease are found in Africa and other 
low- income and middle- income countries, 
which harbour an accumulation of factors 
conducive for high and persistent pneumo-
coccal carriage and transmission including, 
high- density living conditions, poverty and 
high HIV seroprevalence.3–5In 2015, pneu-
mococcal pneumonia accounted for 55.4% 
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(95% uncertainty interval: 31.5–79.1) of lower respiratory 
deaths in all ages.1 Implementation of treatment strate-
gies, which focus on early detection and antimicrobial 
therapy of suspected pneumonia cases, has been difficult 
in Africa.6 Therefore, introduction of an effective vaccine 
against pneumococcal carriage for children is crucial in 
this region as carriage is a prerequisite for disease.
With support from Gavi (the Vaccine Alliance), 34 
African countries introduced the pneumococcal conju-
gate vaccines (PCV7/PCV10/PCV13) into their extended 
immunisation programmes between 2009 and 20157 8 in 
line with WHO recommendations.9 These vaccines have 
been shown to be highly effective in reducing both 
incidence of pneumococcal disease and prevalence of 
carriage by some of the most pathogenic of the 97 known 
pneumococcal serotypes.10 Furthermore, the vaccine indi-
rectly protects the PCV- unvaccinated population against 
pneumococcal carriage and disease by reducing pneumo-
coccal transmission from PCV- vaccinated children who 
are at greater risk of carriage and, therefore, sources of 
transmission.2 11–13 However, PCV’s indirect protection 
on other high- risk populations (including HIV- infected 
individuals) remains to be seen in Africa.11 14 Studies 
conducted in Africa have demonstrated high nasopharyn-
geal carriage of pneumococcus among the HIV- infected 
adults on antiretroviral therapy (ART), with estimated 
point prevalence ranging between 40% and 80%.12 15 
Therefore, it remains uncertain whether the introduc-
tion of PCV in Africa will achieve the sustained direct or 
indirect protection necessary to reduce pneumococcal 
carriage to levels sufficient to interrupt transmission and 
disease.16
Systematic reviews that have been done so far on the 
impact of PCV in Africa have focused on carriage and 
clinical pneumonia endpoints in children.17 18 None have 
summarised these data in the adult or important at- risk 
populations like HIV- infected individuals. We therefore 
plan to synthesise the available published data and update 
the evidence on the impact of the PCV introduction on 
pneumococcal carriage, pneumococcal pneumonia and 
associated mortality in Africa between 2000 and 2019.
ObjECtIvES
General objectives
1. To summarise available data on the impact of the PCV 
on the prevalence of pneumococcal carriage (vaccine 
type - VT and non- vaccine type - NVT) and its impact on 
pneumococcal pneumonia and associated mortality in 
Africa between 2000 and 2019.
Specific objectives
Using data published between 2000 and 2019, this review 
will assess the impact of PCV by:
1. Comparing the trend in pneumococcal carriage preva-
lence in Africa before and after PCV introduction.
2. Comparing the trends in the incidence and/or preva-
lence of pneumococcal pneumonia (invasive and non- 
invasive) in Africa before and after PCV introduction.
3. Estimating the mortality associated with pneumococ-
cal pneumonia in Africa.
MEthOdS
 Information sources, search strategy and study identification
We will conduct a comprehensive literature search in 
PubMed, MEDLINE database, the Excerpta Medica 
Database, the ISI Web of Science (Science Citation 
Index), Scopus and the African Index Medicus to iden-
tify all studies published between 1st January 2000 to 
31st December 2019, meeting our inclusion and exclu-
sion criteria using the literature search strategy outlined 
in table 1. Using a structured screening guide, we will 
screen the reference lists for eligible articles and rele-
vant reviews as well as conference abstracts to identify 
additional sources of information. Search results will be 
compiled and managed using the EndNote X9 citation 
software.
 Eligibility criteria of relevant studies
 Inclusion criteria
Population
Children (0–15 years), adults (15–64 years), the elderly 
(>65 years) and HIV- infected individuals (all ages) 
residing in African countries.
Intervention
PCVs (PCV 7, PCV10 and PCV13) introduction into the 
country’s routine infant immunisation programmes.
Comparators
Ten- year period (2000–2010) before PCV introduction 
versus 10- year period (2011–2019) after PCV introduction.
Outcomes
Percentage difference in the pooled point prevalence 
of pneumococcal carriage post when compared with 
pre- PCV introduction; adjusted prevalence ratios in 
the pooled prevalence of pneumococcal pneumonia 
between post- PCV and pre- PCV introduction; and 
adjusted mortality rate ratios for post- PCV and pre- PCV 
introduction.
Type of studies
We will include randomised control trials, non- randomised 
trials and observational studies reporting prevalence 
of pneumococcal carriage and/or incidence rates for 
disease and/or deaths and were published between 1st 
January 2000 and 31st December 2019 without language 
restriction.
Serotyping methods
For pneumococcal carriage, identification and sero-
typing of S. pneumoniae must be from a pernasal swab 
using culture (as per WHO guidelines,19 PCR (lyt- A gene 
amplification), microarray or based on whole genome 
sequencing (WGS).
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Table 1 Search strategy
Search Search terms and combinations
1 (“Pneumococc*” OR “Strep* pneumo” OR “S. pneumo*” OR “Streptococc*”)
2 (“Pneumococcal vaccines” OR “streptococcal vaccines” OR “Pneumococcal conjugate vaccine”)
3 ((“Africa” OR “Africa*” OR “Algeria” OR “Angola” OR “Benin” OR “Botswana” OR “Burkina Faso” OR “Burundi” OR 
“Cape Verde” OR “Cameroon” OR “Central African Republic” OR “Chad” OR “Comoros” OR “Democratic Republic 
of Congo” OR “Congo” OR “Ivory Coast” OR “Djibouti” OR “Egypt” OR “Equatorial Guinea” OR “Eritrea” OR 
“Ethiopia” OR “Gabon” OR “Gambia” OR “Ghana” OR “Guinea” OR “Guinea- Bissau” OR “Kenya” OR “Lesotho” 
OR “Liberia” OR “Libya” OR “Madagascar” OR “Malawi” OR “Mali” OR “Mauritania” OR “Mauritius” OR “Morocco” 
OR “Mozambique” OR “Namibia” OR “Niger” OR “Nigeria” OR “Rwanda” OR “Sao Tome and Principe” OR 
“Senegal” OR “Seychelles” OR “Sierra Leone” OR “Somalia” OR “South Africa” OR “South Sudan” OR “Sudan” OR 
“Swaziland” OR “Tanzania” OR “Togo” OR “Tunisia” OR “Uganda” OR “Zambia” OR “Zimbabwe”) NOT (“pig*” OR 
“Papua”))
4 (“carriage” OR “Carriage” OR “coloniz*” OR “Coloniz*” OR “colonis*” OR “Colonis*” OR “acquisition” OR “acquir*” 
OR “carrier state” OR “Carrier state”)
5 (“Pneumococc* pneumonia” OR “Community acquired pneumonia” OR “Non- invasive pneumonia” OR “Invasive 
pneumococc* pneumonia” OR “CAP” OR “IPD”)
6 (“mortality rate” OR “case fatality” OR “death rate”)
7 Carriage:
#1 AND #2 AND #3 AND #4
8 Pneumococcal pneumonia and associated mortality:
#1 AND #2 AND #3 AND (#5 AND/OR #6)
9 Filters: Publication date from 2000/01/01 to 2019/12/31; Humans
Pneumococcal pneumonia
For a pneumococcal pneumonia diagnosis among adults, 
a minimum of either (1) symptoms consistent with an 
acute chest infection (at least cough or dyspnoea) or 
(2) new infiltrates on radiograph and (3) pneumococcal 
antigen detection in either blood, urine or pleural fluid. 
For children (1–15 years), the case definition is the 
criteria for adults plus symptoms of fast breathing, chest- 
indrawing and nasal flaring. These definitions have been 
adopted in order to increase the specificity of identi-
fying pneumococcal pneumonia but are limited in their 
sensitivity.
 Study exclusion criteria
1. Any study reporting impact data of vaccines within 
12 months of PCV introduction into routine extend-
ed programme of immunisation and data reported in 
such a way that impact cannot be defined without data 
from within 12 months of PCV introduction.
2. Studies with small sample size (less than 50 partici-
pants), letters, commentaries, narratives and editori-
als, will be excluded as they are likely to have biased 
estimates, and this could affect our estimates.
3. Studies that did not distinguish between pre- PCV and 
post- PCV introduction periods in the data presented.
 data extraction
Three independent reviewers (NLK, TKN and TDS) will 
assess the articles for inclusion based on a predetermined 
inclusion and exclusion criteria. Those included after 
initial screening will be further evaluated for method-
ological quality and presence of bias. Discordance will 
be resolved by discussion between reviewers to reach 
consensus or by a fourth member of the team (KJ). All arti-
cles retrieved will be stored and managed using Endnote 
X9 throughout the review process. A standardised data 
extraction form designed specifically for each outcome 
of interest, will be used to collect information on the 
following parameters:
1. Study identification: name of first author, year of pub-
lication, year of participant inclusion, country, type of 
publication, language of publication.
2. Study characteristics: study design (eg, cross- sectional, 
cohort, case control, clinical trial), setting (hospital, 
outpatient, population, institution (eg, school or care 
facility), urban/rural), period of surveillance/recruit-
ment, sample size, age (mean or median, range), pro-
portion of HIV- infected participants and method of 
confirmation (if any), proportion on ART (if any), pro-
portion PCV- vaccinated (if any), proportion with natu-
ral pneumococcal carriage (VT, NVT, total), diagnostic 
method for pneumococcal carriage detection and se-
rotyping (culture, PCR, DNA microarray, WGS), diag-
nostic criteria for pneumococcal pneumonia, duration 
of follow- up for cohort studies and mortality rates.
3. Epidemiological estimates of pneumococcal carriage: 
prevalence of VT and NVT carriage.
4. Epidemiological estimates for pneumococcal pneumo-
nia: prevalence and/or incidence of pneumococcal 
pneumonia and/or mortality in all subpopulations, 
where reported (infants below age of 1 year, children 
1–4 years, children 5–15 years and adults 16+years), 
the elderly and HIV infected. When estimates are not 
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available or cannot be computed, the corresponding 
authors will be contacted to request for any missing in-
formation of these estimates.
 Appraisal of quality of reporting and the risk of bias
We will assess the quality of reporting of the studies using 
either the Strengthening the Reporting of Observational 
studies in Epidemiology or the Consolidated Standards of 
Reporting Trials checklist depending on the nature of the 
study (observational study or clinical trial).20–22
We will use the 10- item risk of bias tool for prevalence 
studies developed by Hoy et al23 to assess the risk of bias 
for all the studies included using the full text publica-
tions. Bias risk scores will be presented in a table and 
inter- rater agreement will be assessed using a weighted 
Cohen’s kappa statistic.24 25
 data analyses and reporting
We will use the metaprop command provided within 
the STATA software V.15 to analyse the data.26 Hetero-
geneity of studies with similar study characteristics will 
be evaluated by the χ2 test on Cochrane’s Q statistic27 
and quantified using I2 values assuming that I2 of 25%, 
50% and 75% represent low, medium and high hetero-
geneity, respectively.28 Study- specific estimates will be 
pooled through a random effect meta- analysis to obtain 
an overall summary estimate of the prevalence of S. pneu-
moniae carriage, incidence of pneumococcal pneumonia 
and mortality after stabilising the variance of individual 
studies using the Freeman- Tukey double arcsine transfor-
mation.29 For impact of PCV on carriage, the percentage 
change in point prevalence will be calculated to compare 
pooled prevalence estimates in the before and after PCV 
introduction periods. Mortality rate ratios will be calcu-
lated to compare pooled mortality rates for the periods 
before and after PCV introduction. Meta- analysis results 
will be presented on a forest plot. Visual analysis of funnel 
plot and Egger’s test will be done to detect small study 
effect.30 31 All tests will be two- sided and statistical signifi-
cance will be defined as p<0.05. In case of marked hetero-
geneity, a descriptive analysis will be done instead of a 
meta- analysis.
We will report our results according to the Meta- 
Analysis Of Observational Studies in Epidemiology guide-
lines.32 The process with which studies were selected will 
be summarised using a flow diagram. Reasons for study 
exclusion will be described and quantitative data will be 
presented in summary tables and graphs (for trends) 
where appropriate.
 Ethics and dissemination
This systematic review will not require ethical approval as 
we will be using already published data. The findings will 
be summarised in a manuscript and submitted in peer- 
reviewed journals and presented at relevant conferences.
 Patient and public involvement
This systematic review will use published scientific data 
and will not involve patients or members of the public.
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